Cargando…
SAT658 Tirzepatide Reduces The Predicted Risk Of Developing Atherosclerotic Cardiovascular Disease: A Post-hoc Analysis Of The Surmount-1 Trial
Disclosure: E.R. Hankosky: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. H. Wang: Other; Self; Eli Lilly & Company. N.M. Lisa: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. H. Kan: Employee; Self; Eli Lilly & Compa...
Autores principales: | Hankosky, Emily R, Wang, Hui, Lisa, Neff M, Kan, Hongjun, Wang, Fangyu, Ahmad, Nadia N, Stefanski, Adam, Timothy Garvey, W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554341/ http://dx.doi.org/10.1210/jendso/bvad114.106 |
Ejemplares similares
-
SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1
por: Srinath, Reshmi, et al.
Publicado: (2023) -
OR10-05 Improved Mental And Psychosocial Patient-Reported Outcomes Among People With Obesity Treated With Tirzepatide: Results From SURMOUNT-1 Study
por: Poon, Jiat Ling, et al.
Publicado: (2023) -
SAT664 Obesity And Overweight Diagnosis, Physician Prescription And Patient Filling Of Anti-Obesity Medications In US
por: Ezendu, Kyrian, et al.
Publicado: (2023) -
FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023) -
SAT-585 Autoregulation of Adipose Tissue Development
por: Feldman, Brian, et al.
Publicado: (2020)